Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
作者： Fiona Day , Mahesh Kumar , Linda Fenton , Craig Gedye
DOI: 10.1097/CJI.0000000000000146
关键词:
摘要: A 72-year-old male patient was receiving second-line chemotherapy for metastatic squamous cell carcinoma of the skin (SCCS) when he diagnosed with concurrent melanoma (BRAF mutant). Chemotherapy ceased and treated 4 cycles ipilimumab immunotherapy. The experienced clinical benefit durable remission in both malignancies remains free cancer progression 8 months after last cycle ipilimumab. Response SCCS to has not been previously described, however this case recent reports pembrolizumab efficacy confirm critical role immune system pathogenesis suggest further exploration checkpoint immunotherapy treatment disease.
sci-hub.se 参考文章(10)
Anne Lynn S. Chang, Jinah Kim, Richard Luciano, Loretta Sullivan-Chang, Alexander D. Colevas, A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor. JAMA Dermatology. ,vol. 152, pp. 106- 108 ,(2016) , 10.1001/JAMADERMATOL.2015.2705
Susan J. Huang, Dirkjan Hijnen, George F. Murphy, Thomas S. Kupper, Adam W. Calarese, Ilse G. Mollet, Carl F. Schanbacher, Danielle M. Miller, Chrysalyne D. Schmults, Rachael A. Clark, Imiquimod Enhances IFN-γ Production and Effector Function of T Cells Infiltrating Human Squamous Cell Carcinomas of the Skin Journal of Investigative Dermatology. ,vol. 129, pp. 2676- 2685 ,(2009) , 10.1038/JID.2009.151
Trude E Robsahm, Margaret R Karagas, Judy R Rees, Astri Syse, New malignancies after squamous cell carcinoma and melanomas: a population-based study from Norway BMC Cancer. ,vol. 14, pp. 210- 210 ,(2014) , 10.1186/1471-2407-14-210
C. Gedye, A. van der Westhuizen, T. John, Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities Internal Medicine Journal. ,vol. 45, pp. 696- 701 ,(2015) , 10.1111/IMJ.12653
William L. Barrett, M. Roy First, Bernard S. Aron, Israel Penn, Clinical course of malignancies in renal transplant recipients Cancer. ,vol. 72, pp. 2186- 2189 ,(1993) , 10.1002/1097-0142(19931001)72:7<2186::AID-CNCR2820720720>3.0.CO;2-2
M.C. Foote, M. McGrath, A. Guminski, B.G.M. Hughes, J. Meakin, D. Thomson, D. Zarate, F. Simpson, S.V. Porceddu, Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma Annals of Oncology. ,vol. 25, pp. 2047- 2052 ,(2014) , 10.1093/ANNONC/MDU368
Silvia C Formenti, Sandra Demaria, Systemic effects of local radiotherapy Lancet Oncology. ,vol. 10, pp. 718- 726 ,(2009) , 10.1016/S1470-2045(09)70082-8
Tanguy Y Seiwert, Robert I Haddad, Shilpa Gupta, Ranee Mehra, Makoto Tahara, Raanan Berger, Se-Hoon Lee, Barbara Burtness, Dung T Le, Karl Heath, Amy Blum, Marisa Dolled-Filhart, Kenneth Emancipator, Kumudu Pathiraja, Jonathan D Cheng, Laura Q Chow, None, Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. Journal of Clinical Oncology. ,vol. 33, ,(2015) , 10.1200/JCO.2015.33.18_SUPPL.LBA6008
Evan J. Lipson, Serena M. Bagnasco, Jack Moore, Sekwon Jang, Manisha J. Patel, Andrea A. Zachary, Drew M. Pardoll, Janis M. Taube, Charles G. Drake, Tumor Regression and Allograft Rejection after Administration of Anti–PD-1 The New England Journal of Medicine. ,vol. 374, pp. 896- 898 ,(2016) , 10.1056/NEJMC1509268
G. Manson, J. Norwood, A. Marabelle, H. Kohrt, R. Houot, Biomarkers associated with checkpoint inhibitors Annals of Oncology. ,vol. 27, pp. 1199- 1206 ,(2016) , 10.1093/ANNONC/MDW181